Ideaya Biosciences, INC

IDEAYA Biosciences announced positive Q2 2026 financial results, highlighted by a registrational trial success for darovasertib and a strengthened cash position extending runway to 2030.

IDEAYA Biosciences announced the successful closing of its underwritten public offering, raising approximately $323.6 million in net proceeds.

IDEAYA Biosciences and Roche are collaborating on a clinical trial to evaluate IDE892 in combination with RG6505 for MTAP-deleted pancreatic cancer.

IDEAYA Biosciences has filed a new automatic shelf registration statement to maintain its at-the-market equity offering capacity.

IDEAYA Biosciences reported positive Phase 2/3 OptimUM-02 trial results for darovasertib combination, meeting its primary endpoint and paving the way for an NDA submission.

IDEAYA Biosciences announced positive topline results from its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with crizotinib for metastatic uveal melanoma.

IDEAYA Biosciences reported a substantial increase in collaboration revenue and a narrowed net loss in Q3 2025, driven by a new licensing agreement and significant pipeline advancements.

IDEAYA Biosciences reported a significant increase in net loss and operating expenses for Q2 2025, driven by accelerated clinical development, while maintaining a strong cash position to fund operations for at least 12 months.

IDEAYA Biosciences and Gilead Sciences expand their collaboration to evaluate IDE397 in combination with Trodelvy in MTAP-deletion NSCLC, alongside a financial update in a recent 10-Q filing.

IDEAYA Biosciences reports a net loss of $144.2 million for the first nine months of 2024, while highlighting clinical progress across its oncology pipeline and a new licensing agreement.

IDEAYA Biosciences reports its second quarter 2024 financial results, highlighting progress in clinical trials and strategic collaborations.

IDEAYA Biosciences has filed an amendment to its quarterly report to include a previously omitted Rule 10b5-1 trading plan by its Chief Scientific Officer.

IDEAYA Biosciences highlights pipeline advancements, strategic collaborations, and a strong financial position in its 2024 annual report.

IDEAYA Biosciences' 10-K filing details its capital structure, clinical pipeline, and strategic collaborations, highlighting its focus on precision medicine oncology.

IDEAYA Biosciences Chief Accounting Officer Andres Ruiz Briseno reports a 10b5-1 plan transaction involving the acquisition and sale of common stock.

IDEAYA Biosciences Director Wendy L. Yarno acquired 20,000 stock options with an exercise price of $30.57, vesting under specific conditions related to service and annual meetings.

IDEAYA Biosciences reports that Director Jeffrey Stein acquired 20,000 stock options.

IDEAYA Biosciences, Inc. reports that Director Terry J. Rosen acquired 20,000 stock options with an exercise price of $30.57.

IDEAYA Biosciences Director Scott W. Morrison acquired 20,000 stock options with an exercise price of $30.57, vesting under specific conditions.

IDEAYA Biosciences reports a Form 4 filing detailing the acquisition of stock options by Director Catherine J. Mackey.

IDEAYA Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditor selection, and vote on executive compensation.

IDEAYA Biosciences will hold its 2025 Annual Meeting of Stockholders online on June 24, 2025, to vote on director elections, auditor ratification, and executive compensation.

IDEAYA Biosciences will hold its 2024 Annual Meeting of Stockholders online on May 31, 2024, to vote on director elections, auditor ratification, executive compensation, and other matters.

Vanguard Capital Management has reported a beneficial ownership of 5.08% in Ideaya Biosciences Inc., holding 4,834,771 shares as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 7,265,253 shares, representing 8.3% of Ideaya Biosciences, Inc.'s common stock, as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in Ideaya Biosciences Inc. following an internal realignment.

Capital Research Global Investors has disclosed a 6.0% beneficial ownership stake in IDEAYA Biosciences, Inc. common stock.

Federated Hermes, Inc. and affiliated entities have reported a reduced beneficial ownership in IDEAYA Biosciences, Inc. to 3.87% of common stock.

Janus Henderson Group plc has reported an increased beneficial ownership of 7.3% in IDEAYA BIOSCIENCES, INC. common stock as of September 30, 2025.